Tdp 43 Proteinopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TDP-43 proteinopathy is a neurodegenerative disorder characterized by the abnormal accumulation and aggregation of the TAR DNA-binding protein 43 (TDP-43) in the cytoplasm of neurons and glial cells[1]. This proteinopathy is the defining pathological hallmark of amyotrophic lateral sclerosis (ALS) and the majority of frontotemporal dementia (FTD) cases, representing a critical intersection between these two clinically distinct but pathologically overlapping neurodegenerative diseases[2]. [1]
The discovery of TDP-43 inclusions as the primary pathology in ALS and FTD revolutionized our understanding of these conditions, establishing a unified pathological framework that connects what were previously considered separate diseases[3]. TDP-43 pathology is now recognized in over 95% of ALS cases and approximately 50% of FTD cases, making it one of the most important protein aggregates in neurodegenerative disease research[4]. [2]
--- [3]
TDP-43 is a 414-amino acid nuclear protein encoded by the TARDBP gene located on chromosome 1p36.22[5]. The protein contains an N-terminal domain involved in nucleic acid binding, a central glycine-rich region facilitating protein-protein interactions, and a C-terminal prion-like domain that enables aggregation[6]. [4]
In healthy neurons, TDP-43 primarily localizes to the nucleus where it performs essential cellular functions[7]. The protein has a characteristic NLS (nuclear localization signal) sequence that directs its nuclear import and ensures proper subcellular distribution[8]. [5]
TDP-43 participates in multiple essential cellular processes: [6]
DNA Binding and Transcription Regulation: TDP-43 binds to TAR DNA elements and regulates transcription of numerous genes, including those involved in neuronal survival and synaptic function[9].
RNA Processing: As an RNA-binding protein, TDP-43 regulates alternative splicing, RNA stability, transport, and translation[10]. It interacts with hundreds of RNA transcripts, particularly those involved in neuronal development and function.
mRNA Splicing: TDP-43 is a component of the spliceosome complex and regulates the splicing of specific pre-mRNAs, including those encoding proteins critical for synaptic transmission[11].
Stress Granule Formation: Under cellular stress conditions, TDP-43 localizes to stress granules—cytoplasmic organelles that temporarily stall translation to conserve resources[12].
--- [7]
In TDP-43 proteinopathy, the normal nuclear localization of TDP-43 is disrupted, leading to its accumulation in the cytoplasm where it forms insoluble aggregates[13]. These aggregates manifest as: [8]
The aggregation process involves post-translational modifications including: [9]
The cytoplasmic mislocalization of TDP-43 results in a loss of its normal nuclear function—a "loss-of-function" mechanism that contributes to neurodegeneration[18]. This includes: [10]
Cytoplasmic TDP-43 aggregates may also exert toxic effects through: [11]
Emerging evidence suggests TDP-43 aggregates may exhibit prion-like properties, with pathological forms templating the conversion of normal TDP-43 into the aggregated state[20]. This propagation may explain the progressive spread of pathology throughout the nervous system. [12]
--- [13]
TDP-43 pathology is present in virtually all cases of sporadic ALS and approximately 95% of familial ALS cases[21]. The distribution of inclusions follows a pattern that correlates with clinical progression: [14]
Multiple genetic mutations can lead to TDP-43 pathology: [15]
| Gene | Mutation Type | Frequency | [16]
|------|---------------|-----------| [17]
| TARDBP | Missense mutations (M337V, A315T, G348C) | ~5% of familial ALS | [18]
| C9orf72 | Hexanucleotide repeat expansion | ~40% of familial ALS, ~10% sporadic | [19]
| FUS | Mutations causing TDP-43 mislocalization | ~5% of familial ALS | [20]
| SOD1 | Various mutations | ~20% of familial ALS | [21]
The presence of TDP-43 pathology correlates with: [22]
--- [23]
Approximately 50% of FTD cases demonstrate TDP-43 pathology, classified into several subtypes[24]: [24]
The discovery of shared TDP-43 pathology established the ALS-FTD spectrum, recognizing that these conditions represent extremes of a continuous disease spectrum[25]: [25]
The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of both ALS and FTD, further supporting this unified pathological framework[26]. [26]
--- [27]
TDP-43 pathology spreads in a pattern suggesting prion-like propagation along neural networks: [28]
--- [29]
TDP-43 has become an important biomarker target: [30]
TDP-43 pathology helps distinguish: [31]
--- [32]
No disease-modifying therapies specifically target TDP-43 pathology, but multiple strategies are under investigation: [33]
Several clinical trials target TDP-43-related pathways:
The study of Tdp 43 Proteinopathy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent opposing ends of a disease continuum, sharing significant clinical, genetic, and neuropathological features. Approximately 50% of ALS patients exhibit cognitive or behavioral changes consistent with FTD, while up to 15% of FTD patients develop motor neuron disease symptoms. The discovery that TDP-43 inclusions constitute the hallmark pathology in both sporadic ALS (>95% of cases) and the majority of FTD cases (FTLD-TDP) established TDP-43 proteinopathy as the unifying pathological substrate linking these conditions[27:1].
The clinico-pathological overlap extends to specific subtypes: ALS with cognitive impairment shows greater TDP-43 burden in frontotemporal cortex, while FTD with motor features demonstrates more severe spinal cord motor neuron involvement.
The most common genetic cause of both familial ALS and FTD is a G4C2 hexanucleotide repeat expansion in the C9orf72 gene, accounting for approximately 40% of familial ALS, 25% of familial FTD, and 5-10% of sporadic cases[28:1]. Three non-mutually exclusive mechanisms have been proposed for C9orf72-mediated toxicity:
Notably, C9orf72 expansion cases demonstrate TDP-43 pathology at autopsy, suggesting that C9orf72 dysfunction ultimately converges on TDP-43 aggregation as a final common pathway[29:1].
Shared mechanisms between ALS and FTD include:
TDP-43 undergoes extensive post-translational modifications (PTMs) in disease states:
Phosphorylation: Hyperphosphorylation at serine residues (particularly S409/S410, S403/S404) represents one of the earliest disease markers. Phosphorylation stabilizes pathological aggregates and prevents their degradation[30:1].
Ubiquitination: Disease inclusions are heavily ubiquitinated, with K48-linked ubiquitin chains predominant.
C-terminal truncation: TDP-43 fragments spanning residues 216-414 are particularly aggregation-prone and form the core of disease inclusions[31:1].
Acetylation: Acetylation at lysine residues within the RNA recognition motifs reduces TDP-43's RNA-binding affinity and promotes aggregation.
A hallmark of TDP-43 proteinopathy is redistribution from nucleus to cytoplasm:
Under cellular stress, TDP-43 localizes to stress granules. In disease states:
Given that TARDBP mutations cause ALS in ~4% of familial cases, gene silencing approaches offer targeted strategies:
ASOs are synthetic oligonucleotides that hybridize to target RNA:
Pharmacological approaches include:
TDP-43 proteinopathy represents a molecular bridge connecting ALS and FTD, with convergence on common pathological mechanisms. While no disease-modifying therapies specifically targeting TDP-43 have reached clinical use, multiple approaches including gene therapy, ASOs, and small molecule modulators are in development.
Ling SC, Polymenidou M, Cleveland DW. 'Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis'. Neuron. 2013. ↩︎
Rascovsky M, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011. ↩︎
Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006. ↩︎
Ou SH, Wu F, Harrich D, García-Martínez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995. ↩︎
Johnson BS, Snead D, Lee JJ, McCaffrey JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009. ↩︎
Buratti E, Baralle M. The molecular link between ALS and TDP-43. Adv Nutr. 2013. ↩︎
Chattopadhyay B, Bhaduri T, Lindholm V, et al. TDP-43 nuclear export and neurodegeneration in amyotrophic lateral sclerosis. J Mol Neurosci. 2016. ↩︎
Sephton CF, Good SK, Atkin S, et al. TDP-43 is a developmentally regulated protein in central nervous system neurons. J Biol Chem. 2010. ↩︎
Tollervey JR, Curk T, Rogelj B, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011. ↩︎
Highley JR, Kirby J, Jansweijer JA, et al. Loss of nuclear TDP-43 in ALS causes altered expression of splicing regulators. Neuropathol Appl Neurobiol. 2014. ↩︎
Bosco DA, Lemay N, Ko HK, et al. Mutant FUS proteins that cause ALS incorporate into stress granules. Hum Mol Genet. 2010. ↩︎
Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and requires autosomal recessive FUS mutations. Neuron. 2010. ↩︎
Davidson YS, Raby SA, Foulds PG, et al. TDP-43 pathological changes in early onset familial FTD with TDP-43 mutations. Acta Neuropathol. 2011. ↩︎
Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and ALS. J Neurol Sci. 2008. ↩︎
Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009. ↩︎
Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Brain Res. 2009. ↩︎
Igaz LM, Kwong LK, Chen-Plotkin A, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem. 2009. ↩︎
Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013. ↩︎
Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. 'Prion-like disorders: blurring the divide between translational and signaling research'. Neurology. 2010. ↩︎
Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007. ↩︎
Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. ALS-related TDP-43 pathology in the spinal cord, brainstem, sensorimotor cortex, and cerebellum. Acta Neuropathol. 2013. ↩︎
Chio A, Pagano M, Servo S, et al. 'TARDBP mutations in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a population-based study'. J Neurol Neurosurg Psychiatry. 2012. ↩︎
Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTD-TDP-43 pathology. Acta Neuropathol. 2011. ↩︎
Ferrari R, Kapogiannis D, Huey ED, Momeni P. 'FTD and ALS: a tale of two diseases'. Curr Alzheimer Res. 2011. ↩︎
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron. 2011. ↩︎
Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013. ↩︎
Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 2006. ↩︎ ↩︎
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. 2011. ↩︎ ↩︎
Liu Y, Yu JT, Zong Y, et al. C9ORF72 mutations contribute to ALS and FTD. 2016. ↩︎ ↩︎
Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 2008. ↩︎ ↩︎
Zhang YJ, Xu YF, Cook C, et al. C-terminal fragments of TDP-43 in neurodegenerative diseases. 2009. ↩︎ ↩︎
Wolozin B, Ivanov P. Stress granules and neurodegeneration. 2019. ↩︎ ↩︎
Xie L, et al. Context-dependent Interactors Regulate TDP-43 Dysfunction in ALS/FTLD. bioRxiv. 2025. ↩︎